Amicus Therapeutics, Inc. (FOLD) is listed as one of the 13 Best Healthcare Stocks to Buy Under $10. Analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc., with a price target of $20.00. The company is focused on developing medicines to treat metabolic diseases, including Fabry disease and Pompe disease.

Despite Q1 revenue misses for PomOp and Galafold, Amicus Therapeutics, Inc. has maintained a positive outlook for GAAP profitability in H2 2025. The company’s strategic positioning and pipeline expansion, especially with the in-licensing of DMX-200 for FSGS, have contributed to the positive rating by the analyst.

The trends suggest confidence in Amicus Therapeutics, Inc.’s operations and its ability to manage costs effectively. The company’s commitment to boosting long-term growth prospects and expanding its product offerings through pipeline expansion supports the positive outlook from the analyst. Amicus Therapeutics, Inc. aims to deliver innovative treatments for rare diseases.

While Amicus Therapeutics, Inc. shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. Investors looking for undervalued AI stocks can explore other options. The company’s focus on developing precision medicines for metabolic diseases remains a key part of its strategy for future growth and profitability.

Read more at Yahoo Finance: TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT